Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $10
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $11 to $10.
Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $11 to $10.